Literature DB >> 27836793

European policies in the management of tuberculosis among migrants.

Lia D'Ambrosio1, Rosella Centis2, Masoud Dara3, Ivan Solovic4, Giorgia Sulis5, Alimuddin Zumla6, Giovanni Battista Migliori7.   

Abstract

Globally 10.4 million new tuberculosis (TB) incident cases were estimated to have occurred in 2015, of which 3% were reported in the World Health Organization European Region. Importantly, about 25% of the global multidrug-resistant TB (MDR-TB) cases are reported in the European Region, representing one of the greatest challenges to TB control; these are reported particularly in the countries of the Former Soviet Union. Over a quarter of TB cases in the European Union and European Economic Area (EU/EEA) are reported among foreign-born individuals. In line with the recent increase of migration flows towards Europe, TB among migrant populations is also on the rise, emphasizing the need for a better understanding of the TB trends at the regional and sub-regional levels, and of the existing policies on migrants and refugees. The present article is aimed at describing the policies and practices of European countries with a low and intermediate TB incidence with regard to the detection and management of TB and latent TB infection (LTBI) among refugees in Europe.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Europe Region; LTBI; Refugees; Screening practices; Survey; TB

Mesh:

Year:  2016        PMID: 27836793     DOI: 10.1016/j.ijid.2016.11.002

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Demographic predictors of active tuberculosis in people migrating to British Columbia, Canada: a retrospective cohort study.

Authors:  Lisa A Ronald; Jonathon R Campbell; Robert F Balshaw; Kamila Romanowski; David Z Roth; Fawziah Marra; Victoria J Cook; James C Johnston
Journal:  CMAJ       Date:  2018-02-26       Impact factor: 8.262

2.  Multidrug-Resistant Tuberculosis In A Referral Center In Rome: 2011- 2016.

Authors:  E Girardi; A Di Caro; A Cannas; O Butera; G Gualano; M P Parracino; C Venditti; A Mazzarelli; F Palmieri
Journal:  Infect Drug Resist       Date:  2019-10-18       Impact factor: 4.003

3.  The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review.

Authors:  Christina Greenaway; Manish Pareek; Claire-Nour Abou Chakra; Moneeza Walji; Iuliia Makarenko; Balqis Alabdulkarim; Catherine Hogan; Ted McConnell; Brittany Scarfo; Robin Christensen; Anh Tran; Nick Rowbotham; Marieke J van der Werf; Teymur Noori; Kevin Pottie; Alberto Matteelli; Dominik Zenner; Rachael L Morton
Journal:  Euro Surveill       Date:  2018-04

4.  The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review.

Authors:  Christina Greenaway; Manish Pareek; Claire-Nour Abou Chakra; Moneeza Walji; Iuliia Makarenko; Balqis Alabdulkarim; Catherine Hogan; Ted McConnell; Brittany Scarfo; Robin Christensen; Anh Tran; Nick Rowbotham; Teymur Noori; Marieke J van der Werf; Kevin Pottie; Alberto Matteelli; Dominik Zenner; Rachael L Morton
Journal:  Euro Surveill       Date:  2018-04

5.  Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe.

Authors:  Alexandra Jablonka; Christian Dopfer; Christine Happle; Georgios Sogkas; Diana Ernst; Faranaz Atschekzei; Stefanie Hirsch; Annabelle Schäll; Adan Jirmo; Philipp Solbach; Reinhold Ernst Schmidt; Georg M N Behrens; Martin Wetzke
Journal:  Int J Environ Res Public Health       Date:  2018-06-14       Impact factor: 3.390

6.  Knowledge, attitudes, beliefs, and stigma related to latent tuberculosis infection: a qualitative study among Eritreans in the Netherlands.

Authors:  Ineke Spruijt; Dawit Tesfay Haile; Susan van den Hof; Kathy Fiekert; Niesje Jansen; Degu Jerene; Eveline Klinkenberg; Ieva Leimane; Jeanine Suurmond
Journal:  BMC Public Health       Date:  2020-10-23       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.